Survival Analysis for Patients With ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated With Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Oncologist - United States
doi 10.1634/theoncologist.2019-0728
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology
Oncology
2016English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Case Report of Non-Small Cell Lung Cancer With STRN-ALK Translocation: A Nonresponder to Alectinib

Journal of Nihon University Medical Association
2019English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

Treating Patients With ALK-positive Non-Small Cell Lung Cancer: Latest Evidence and Management Strategy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Fever and Survival With Drug-Treated Non-Small Cell Lung Cancer.

Kurume Medical Journal
Medicine
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy